EssilorLuxottica Société anonyme (EL) Earnings Call Transcript
February 11, 2026
Earnings Call Speaker Segments
Hello everyone, Giorgio Iannella here, speaking on behalf of the IR team. We appreciate your participation in the EssilorLuxottica management call covering full year 2025 results. Francesco Milleri, our Group Chairman and CEO, along with Deputy CEO Paul du Saillant and CFO Stefano Grassi, will guide you through the business and financial highlights from last year. Following their presentations, a 30-minute Q&A session will take place. Should you wish to ask a question, please press * followed by 5. We kindly request that you keep your questions to a maximum of two. With that, I'll hand it over to Francesco.
Good to have you all back, and thanks for being with us today. It's great to reconnect and to update you on how we're executing our new strategy, which is plainly fueling momentum across the group's business. That aligns with our plans, and I think it will show up increasingly in the near term, since the new projects, products, and medical services will feed straight through into the numbers. For EssilorLuxottica, 2025 was a year of sharp acceleration as we carry out a deep transformation from a traditional optical company into a leading medtech, data-driven group. That wider scope now defines and clarifies our core business, strategic focus, and investment priorities better than before. Shaping the future of health and human performance is the group's new ambition. This evolution is the key engine behind our faster revenue growth and what drives the positive progression of our profits. Revenue rose strongly in the fourth quarter, reflecting solid performance across our overall business and further reinforced by our clear leadership in wearable and medtech. We're confident this trajectory will continue, which confirms the strength of our vision and the excellence of our execution.
Later, Stefano is going to take you through the numbers on our financial performance. What I want to flag now is that at constant currency, revenue growth came in above 18% for the fourth quarter and at 11% for the full year. That marks the first time in our history we have seen a double digit figure. Full-year revenue was €28.5 billion, and adjusted operating profit came to 4.5 billion, even after a €300 million headwind from US tariffs and materially adverse exchange rates. The strength of our operations is clearly demonstrated by free cash flow of 2.8 billion, which is €400 million above last year. Right now, the new category we have built in AI glasses sits at the heart of this journey. In 2025, we sold more than 7 million units of AI glasses, with exponential growth powered by the strength of our iconic brands Ray-Ban and Oakley across every geography and channel. Making this success of our wearable brands possible has been our unique logistic and distribution footprint — 18,000 stores in retail and 300,000 partners in wholesale — which forms the most powerful go-to-market platform for a product that is first and foremost a vision care device. That view gets further reinforcement from rapidly growing attachment rates for prescription lenses and the already high penetration of photochromic lenses, which together are delivering a strong rise in daily usage and confirming how relevant this category is for all consumers.
Wearables have really become a normal part of life now. As proof of how well we can launch this new category and widen what it covers, the Oakley Vanguard that came out recently opens up fresh use cases in sport as well as lifestyle. There's more to come on brands and features, with growing personalization not just in everyday and social settings but in professional work too. Multiple projects are already in motion with banks, consulting firms, and healthcare institutions, which opens up bigger and at times unexpected market opportunities. AI glasses aren't merely the next step for traditional eyewear; above all they're a new digital platform that unites vision correction, biosensors, audio, cameras, and artificial intelligence in one system. We grow more convinced that over time this category could replace the mobile phone as the main personal computing interface, in personal as well as professional settings. During 2025, our plan has centered on growth and scale. We're convinced that leadership and steady market share in this strategic area matter greatly for the future of our medtech vision. This acceleration demands considerable upfront investments in both OPEX and CAPEX across R&D, operations, marketing, and communications. As expected, those initial investments show up in our P&L, yet the group still delivered record earnings results.
With our medtech and wearable segments now reaching scale, we anticipate profit accelerating and operating margin regaining momentum at both EssilorLuxottica and across the entire optical and medtech industry. The company's future direction is now anchored in a clear, well-executed strategy built on the emerging field of oculomics. That lets us broaden our scope beyond vision correction into medical support and early detection of metabolic, neurological, and cardiovascular conditions. Consistent with this vision, our journey will keep extending into advanced health technologies, predictive medicine, diagnostic instruments, and clinical practices, surgical applications included. Among our most important achievements has been integrating, in a genuinely holistic manner, AI glasses as a consumer-facing evolution alongside the data-driven medtech, healthcare, and clinical business. You'll see our M&A approach evolve, with growing emphasis on startups in vertical medical AI, advanced diagnostics, and support for clinical studies. Simultaneously, we'll keep enhancing and expanding our logistic and distribution footprint via both internal and external growth across physical retail and e-commerce. The concurrence of these two dimensions—digital and physical—combined with our strong medical reputation, is what we believe renders our strategy genuinely unique and nearly impossible to replicate.
And last, when it comes to hearing aid glasses, we keep putting money into a vertical use of our tech in audio, which brings in fresh customer segments and extra revenues. We hold high hopes for the release of new products during this year's second half, together with our plan to broaden the audio feature across our wearables via a subscription-based model. To wrap up, we have finished a remarkable year and begin the new one with strong confidence and clear plans to lead at the forefront of the convergence of multiple sectors and different industries into glasses. That is the reason EssilorLuxottica is taking leadership across the whole medtech space. One final word on our financial roadmap: although we confirm we are fully on track with our long-term outlook going back to March 2022, today we are updating it, with plans to deliver over the next 5 years solid growth of revenues and operating profits that is broadly aligned. With that, I will now pass things to Paul. Thank you.
Thank you, Francesco, and hello everyone. It's great to reconnect with you. As you've heard, EssilorLuxottica took additional decisive steps in 2025 along its strategic journey and delivered solid financial results, driven by an ambitious vision, strong execution, and a relentless focus on innovation. This performance rests on our best-in-class manufacturing and logistics platform, our resilient global supply chain, and a unique omnichannel distribution model that lets us scale innovation efficiently and consistently across markets. Today, I'd like to step back and focus on what lies at the very core of our vision and strategy in the traditional business — namely, the scientific ecosystem we're building around eye health. Let me begin with lens innovation and myopia management in particular, a field we've been investing in for almost half a century and where we further strengthened our leadership in 2025. Stellest has become a global reference in myopia management, backed by robust, long-term clinical evidence, and is now worn by millions of children worldwide. Importantly, Stellest remains the first and only spectacle lens to have received FDA market authorization in the United States. That is a decisive recognition of myopia management as a medical treatment.
During 2025, we made a significant move forward by launching Stellest 2.0 in China — the most advanced lens we've introduced for myopia management so far. Drawing on our fundamental research at the neurobiological level, we maximized both the asphericity and the lens power of the microlenses, which produced axial length growth that was nearly two times lower at 12 months with Stellest 2.0 compared with the prior generation. Rollout of this new generation is underway in EMEA, and we will seek authorization from the FDA. Simultaneously, we're engaging earlier in the patient journey. Through the Stellest plano solution, we address children who are at risk of developing myopia, grounded in clinical evidence demonstrating that delaying onset can yield long-term benefits comparable to years of slowed progression. This represents a shift from management toward evidence-based prevention — a meaningful evolution. Our strategy in myopia is intentionally multi-technology and multi-brand. Next to Stellest, SightGlass Vision DOT Technology, which is commercialized under Nikon and Kodak in China, keeps gaining strong traction, strengthening our portfolio and giving eye care professionals a broader range of clinically validated solutions across different price points. Consequently, in 2025, total revenue from our myopia management portfolio rose by 22%. Outside myopia, innovation throughout our lens portfolio stays robust.
When it comes to presbyopia, labels like Varilux, Nikon, and Shamir keep rolling out designs that blend optical precision, personalization, and comfort, powered by AI-driven modeling. Transitions, which extends light management benefits across prescription, plano, and smart eyewear, is increasingly turning into a standard feature in connected glasses. In frames, 2025 brought strong brand momentum and creative activation throughout our portfolio. On the licensing front, we extended our long-term partnership with Burberry through 2035, reaffirming a collaboration rooted in craftsmanship and innovation, and we introduced the first-ever collaboration between Miu Miu and Puyi Optical, showing our ability to blend exclusivity, design excellence, and retail leadership, particularly in Asia. Across our proprietary brands, we further strengthened Ray-Ban's creative leadership by naming ASAP Rocky as its first-ever creative director. We marked Oakley's 50th anniversary, and we are now seeing the brand gain exceptional global visibility through its presence at the Winter Olympic in Italy. Science sits at the core of all our initiatives. Last year, we formalized this commitment by creating our Scientific Advisory Committee, bringing together five world-class experts across physics, mathematics, ophthalmology, bioethics, and neuroscience, including Nobel Prize and Fields Medal laureates. Their role is to challenge us, guide us, and help us explore new frontiers from oculomics to AI and neuroscience, always with the patient in mind in areas of human health where ethic matters as much as innovation.
Open collaboration is how we're strengthening the ecosystem around us. Research at the crossroads of optics, bioengineering, and artificial intelligence keeps moving forward thanks to our partnership with the Politecnico di Milano, and the future of connected vision devices is being shaped by the joint Smart Eyewear Lab. Being part of the Collaborative Community on Ophthalmic Innovation lets us help build global standards and consensus in myopia, AI, and data-driven ophthalmology. We're also putting money into application-specific semiconductor design through our collaboration with Chips IT, which will enable the next generation of smart and medical eyewear. And at our Bastille R&D lab in Paris, teams are working right at the frontier between vision science and neuroscience, exploring how the brain processes and transmits visual signals. Deepening our grasp of perception and cognition — and unlocking the next wave of optical and neuro-adaptive solutions — depends on this research. Sustainability stays a fundamental pillar of our strategy, steered by a clear roadmap spanning climate, circularity, responsible operation, and social impact. Our efforts earned recognition this year from leading external benchmarks. CDP gave us an A- rating for climate, which places EssilorLuxottica among A-list organizations. At the same time, our Standard & Poor's Global Corporate Sustainability Assessment score came in at 66, securing the third position in our industry worldwide out of more than 250 assessed companies.
So in summary, 2025 proved that EssilorLuxottica’s growth rests on a distinctive mix of clinical science, deep technology, and industrial scale. Whether it’s medtech or neuroscience, eyewear or eye health, we aren’t just innovating alongside our industry — we’re redrawing what its boundaries are. And with the new long-term outlook we’ve set out, we’re approaching the coming 5 years with firm ambitions for our financial delivery. With that, I’ll pass things over to Stefano now. Thank you.
Thanks, Paul, and welcome everyone to our full year 2025 earnings results. We finished another record year for EssilorLuxottica, with revenue up 11% at constant currency — nearly twice the 6% growth we achieved in 2024. North America, EMEA, and Asia-Pacific all posted double-digit gains, while Latin America had a high single-digit year. Q4 was actually the strongest quarter of the whole year in what was an outstanding 2025. Our top line rose 18.4% at constant currency and 12.1% at current exchange rates. These figures are even more impressive when you consider that in Q4, Supreme and Heidelberg became fully comparable, since both were included in 2024 and 2025, fully comp for our reporting. In Q4, our North American business was up 24%, EMEA delivered 16% sales growth, Asia-Pacific was up 12%, and finally, Latin America delivered an 8% sales lift in the quarter. One last note on foreign exchange: for the third consecutive quarter, we unfortunately have some headwinds in our results, with roughly 6 percentage points of difference between constant and current exchange results. As usual, the main driver is the US dollar, which devalued by approximately 8 percentage points year-over-year against the euro.
Given those currency levels, you could still anticipate certain currency headwinds over the course of 2026. So, as we typically do, let's examine the four regions more closely. Within North America, we posted top line growth of 23.8% up at constant currency. That figure represented twice the pace of growth we achieved in North America across a third quarter in which our revenue rose 12%. What I believe is perhaps even clearer is the differing pace between the first half in North America, which saw 5% growth at constant currency, and the second half, when we posted 18% growth at constant currency. Across our Professional Solutions, our B2B business, our independent channels, our key accounts, and our department stores, all were positive. Meanwhile, when we look at sales through our e-commerce partners, there we find revenue in negative territory for Q4. Turning to our product category, frames rose triple digit owing to an outstanding performance from our AI glasses category, yet optical frames also delivered solid growth in the quarter, while our lens business in Q4 was flattish. Looking at our frame brands, Ray-Ban and Oakley climbed triple digit.
Turning to the lens side of our business, we're beginning to see solid traction with Stellest — the first and only FDA-approved lens myopia solution, which is now offered in the United States and is currently receiving orders across more than 4,000 doors in North America. One last remark regarding price mix, which I'd characterize as strong in both lenses and frames. Let's now turn to Direct to Consumer. Within Direct to Consumer in North America, our e-commerce operation came in just a touch under double digit for the quarter, while our retail business posted high single-digit comp sales in Q4. Sunglass Hut rose 9%, and LensCrafters gained 7% in Q4. I'd call that a very compelling story proposition for our Direct to Consumer business. A few quick highlights on LensCrafters: we're reporting yet another great quarter. In Q4 we recorded the two single days with the highest revenue in LensCrafters history, and that took place during the insurance days at the end of December. Our lens mix kept improving over the quarter. We have greater penetration of Transitions. We have a successful adaptive progressive lens powered by Shamir across all the different LensCrafters stores in North America.
Every one of the fundamental KPIs — price mix, eye examination, traffic, and conversion — was moving in the right direction. Turning to the sun banner, Sunglass Hut: Q4 was, quite simply, the strongest quarter in 2025, and that came against a tough comparison base, since last year's Q4 comp sales were in fact the best in 2024. So the best result on top of the best result last year. Our international and core location performed at what I would call a fairly even pace. AI glasses remain a key driver arc of our growth, with both Ray-Ban Meta and Oakley Meta delivering outstanding results. Before I move to EMEA, let me note that as we enter 2026, our Direct to Consumer trend in North America is accelerating further. We're only one month into the year, but obviously we're off to a very promising start. Moving on to EMEA: EMEA delivered 15.7% growth in Q4, the 19 consecutive quarter of growth in the EMEA region, the best quarter in 2025 for Professional Solutions, the best quarter in 2025 for Direct to Consumer, with both segments delivering at a double-digit pace. Within the region, Italy, Spain, UK, Turkey, Eastern Europe, and Middle East posted a double-digit quarter at constant currency, while Scandinavia was up high single digit, and France delivered a fourth quarter in a low single-digit territory.
Looking at the two distribution channels within Professional Solutions, our frame business turned in an excellent quarter, driven by AI glasses and the optical business, with growth largely coming from volume as well as price mix. In the EMEA region, we're pleased with how our luxury portfolio performed. It grew at a mid single-digit pace. I'd highlight Chanel, Prada, and Miu Miu. Turning to the lens side of the business, the other products category, Transitions and Varilux did well, and Stellest grew at a double-digit rate, with that growth on the lens side driven very much by volume. Now let's move to the other channel and take a look at Direct to Consumer. Comps landed in the high single-digit territory for optical in EMEA and at a double-digit level in the sun portion of our EMEA business. On the optical business, I'd say we're very much in the final stage of integrating the former GrandVision banners into EssilorLuxottica's operating machine. To give you a sense of it, penetration of EssilorLuxottica products in our frame assortment stands at approximately 85%, and lens assortment penetration across the banners in the EMEA region is approximately 90%.
The subscription offering is now live in roughly 19 countries, and it accounts for 22% of optical revenue in the region — that's a couple of percentage points above where we stood in the fourth quarter of last year. One more thing worth mentioning: tele-optometry is another significant asset for us. To illustrate just how important and how successful this asset proved in 2025, I can tell you that we surpassed 200,000 eye exams delivered via tele-optometry in 2025. That figure is 40% higher than the 2024 eye examination count. Turning now to sun, the fourth quarter was in fact the strongest quarter for sun in 2025, with the UK, Turkey, and Italy all growing at a double-digit pace. The top door in the EMEA region for sun — you'll recall these are the 50 largest ones we have — posted a double-digit quarter. Whether you're in Dubai or Paris, in Madrid rather than Istanbul, Sunglass Hut is increasingly the go-to destination for sun across the EMEA region, and that obviously makes everyone on the sun team and at EssilorLuxottica extremely proud. Now let's shift gears and move to East in the Asia-Pacific region.
Our top line rose 11.6%, marking yet another robust quarter for this region, and India, Australia, and Southeast Asia each grew at a double-digit rate. China and Japan posted high single-digit gains, and Korea saw mid single-digit growth over the course of Q4. Myopia is a key asset for us here. In China, the myopia category turned in another excellent quarter of double-digit growth, and revenues there now represent roughly 27% of total Greater China business. Demand remains robust — and I'd say it stays robust across every myopia solution we offer, from Stellest through to Kodak and Nikon, which use the other technology, the DOT one. Turning to our other category, the frame business had a strong quarter across pretty much every region, with sales fueled by volume as well as by price mix. Ray-Ban, Oakley, and the luxury portfolio all posted double-digit increases in Q4. As for our Direct to Consumer channel — the other channel — we're very pleased with our key banners in mainland China. Those banners achieved double-digit growth quite consistently through 2025, in each and every quarter.
The region's other top optical banner, OPSM, recorded a low single-digit comp sales quarter, and its key metrics for premium lenses, Transitions, and the myopia solution all showed improvement compared with Q4 of last year. Now let's move to the final region in the pipeline, which of course is Latin America. In Latin America, Q4 came in up 7.6%. That represents an acceleration from Q3, when, as you'll recall, we posted 5.2% top line growth. Professional Solutions and Direct to Consumer each delivered a high single-digit quarter. I'd describe it as a really strong quarter pretty much across the region's individual countries. Brazil and Argentina grew by double digits. Mexico, Colombia, and the rest of Latin America posted a mid single-digit quarter. In Brazil, the largest country, our frame business grew double digit, as did Oakley and our luxury portfolio, with price mix serving as very much the main driver of growth there. Turning to our lens business in Brazil, we saw a low single-digit quarter, yet every key asset — Transitions, Varilux, Eyezen — posted positive growth in Q4.
One final note on Óticas Carol, as always: those 1,400 stores are turning in a double-digit quarter, and I'd say that at Óticas Carol, AI glasses are beginning to matter more and more and are really instrumental to the growth and success story for that banner. One last note now on the Direct to Consumer region. Within Direct to Consumer, the sun banner came in just slightly under double digit. Ray-Ban stores, Sunglass Hut stores, and Oakley stores were very much the main driver behind our comp sales growth in Q4, while on the optical side of our business, the biggest GrandVision footprint — the one we have in Mexico — posted high single-digit comp sales. So we're now wrapping up our journey through all four of our regions, and now let's look a bit more closely at our profit and loss, as usual. We'll be looking at the full year profit and loss, and as usual I'll take you through the key line items at constant currency, and I won't spend time on sales, since we largely covered that earlier. The first line item is gross margin. Our gross margin is down 260 basis points in '25 versus 2024.
It's really a mix of two things. On one hand, there's the tariff effect, and the gap here is big when you compare the second half with the first half of the year, since those tariffs hit for two quarters during the 2025 second half, whereas in the first half, the effect landed mostly in the second quarter. The second piece, which matters a lot, is the percentage dilution that comes from AI glasses, which in the second half of the year, because AI glasses contributed more to our growth rate, weighed much more heavily on our margin. On a full year basis, just to paint a broader picture for you, roughly a third of the gross margin impact comes from tariffs, and two-third of it is attributable to AI glasses. Now let's look a bit at our OPEX. Our OPEX as a percentage of revenues is 170 basis points below 2024 levels. Here, on one side, you have the investment we keep making to support our new strategic initiatives. We discussed, during the different region, the performance on AI glasses. Francesco and Paul explain our long-term strategy on medtech, the development of the audiology business, and those investments, the deployment of those initiatives across the different channels, across the different geography, clearly have an impact on our selling, marketing, and also G&A.
Alongside that, we’re carrying out an in-depth review of how our organization is set up — checking whether all our people are deployed in the right places — and we’re working to realign the organization around our strategic priorities. Overall, if you look at operating profit as a percentage of revenue, it’s down 70 basis points at constant effects and roughly 100 basis points at current exchange rate. Below operating profit, our cost of debt is higher versus last year as a result of a higher interest rate environment. Clearly, that is the main driver behind it. As for the tax rate, we have a slightly more favorable one, pretty much as a result of a different country mix. That leads to total net profit for EssilorLuxottica full year ’25 down 50 basis points at constant effects and 70 basis points at current exchange rate. Now the last chapter of this journey before the Q&A session is clearly an important one, and it is represented by our cash flow. I’d start by giving one number that I believe tells you everything: €2 billion 796 million of free cash flow generation during the course of 2025. This represents the record-high free cash flow generation.
We hit those numbers even with significant tariff pressure and a sizable currency drag. One final point on net debt to EBITDA, which now stands at 1.7 as of the close of 2025 — a clear sign that we can both keep a strong balance sheet and put money into every one of the group's strategic priorities at the same time. So, as always, let's hand things over to the operator for the usual Q&A.
Ladies and gentlemen, the Q&A session is starting now. Our first question is from Oriana Oriana at Intesa Sanpaolo.
Yes, good evening, and thanks for taking my two questions. My first one concerns how wearable sales are developing across channels. Looking at the full-year results, could you share the channel mix for wearable revenues and say whether you see different trends ahead for the two channels? My second question is about the margin outlook for wearables. How do you see operating costs developing this year and next year for the wearables? At what production volume level do you expect economies of scale to start helping margins improve? Thank you.
Hi Oriana, good evening. I think the first question here is about the channel. Whether it’s Professional Solution or wholesale, that’s the one that will genuinely give us the strongest opportunity to grow in every market. And if we consider Direct to Consumer — especially the physical network we operate, those 18,000 stores that we directly manage — that will truly be the decisive factor that can unlock growth in wholesale sales of our AI glasses. AI glasses are now more commonplace. They remain something different from ordinary glasses; they have to be tested, tried, and sometimes explained. The fact that we have this very strong professional network helps a great deal with how quickly we actually enter the market. Then Professional Solution follows, also mirroring the strategy we use in our retail stores. I believe the mix will be much larger on the wholesale side, because in wholesale the number of doors is far greater than in our retail, but the number of units per single door will remain, in the near future, higher in our own retail, where we can take care and better define the communication strategy that will also help the independent optician and consumer electronics partners better understand how to sell AI glasses and wearables.
Thanks. Good evening, Oriana — I'll address the second question you raised tonight, which concerns the margin outlook for the AI glasses. There are a couple of factors that you should keep in mind here. First, in line with the pattern from the past 2 years, we do anticipate an upward shift in price mix driven by product innovation. Consider that we set the launch price of the original Ray-Ban Stories at $299, and look at how Ray-Ban Meta pricing has evolved — clearly it is heading in exactly that direction. We think that will occur once more, powered by innovation, just as it has in other areas of the business. Then the second element of the equation is cost. My belief is that scale will help bring cost down progressively over time.
Chiara Battistini from JP Morgan has our next question. The line is yours.
Good evening, everyone, and thanks for taking my questions. My first one concerns wearables and the expansion of additional production capacity. Given some of the remarks we heard from Meta over the past few weeks, I was hoping you could update us on how we should think about capacity expansion, and also about CAPEX for 2026 in light of potentially adding capacity. On the second question, you mentioned myopia management grew 22%. Could you update us on how large myopia management was in 2025, and on how we should think about the priorities for myopia management in 2026, particularly given the new push in the US? Thank you.
Chiara, I'll respond to the first question about how capacity evolves. Let me frame this a bit more broadly. My view is that we'll possess whatever capacity is required, whether in-house or from outside, to handle the demand we'll encounter over the next few years. We're making our plans along those lines, working closely together with Meta. Then, Paul, the second question concerns myopia?
Sure, I'll take the second one. Thanks, Chiara. Just to provide a bit of context, myopia activity across the group has risen 22% worldwide, as was mentioned. As of today, that activity is primarily in China and Europe. Regarding China, just to keep in mind — I believe Stefano shared a data point — nearly 30% of the total China activity is based in myopia management. That's fairly significant. The priority for '26 is quite straightforward, and I did mention it in my brief talking point. The first is to keep deploying the complete solution we have in place with hospitals and the government in China, specifically Stellest, Stellest 1, Stellest 2, and the DOT Technology, which provides us a full platform to serve different price points and needs. The second is to keep rolling out in Europe and launch Stellest 2.0, the newest technology platform in Europe. Naturally, a major focus for our American colleagues is that, after the FDA approval we secured back in September, we are now truly in the full launch process for Stellest 1.0, the first platform, as we get ready to file Stellest 2 with the FDA as well.
At the moment, our focus is on getting the doctors, the optometrists, and the parents familiar with this completely new solution in the US — the first ever available for children — and we already have close to 4,000 doors that have been trained and equipped, and of course we are expanding distribution to many more doors as we speak. That is really the plan for us this year. It's a big priority for the teams. It's also a fantastic way to connect to the medtech strategy that was explained, because this is taking us into the doctor's office, into the clinic, into the eye hospital space.
Anne-Laure Bismuth from HSBC has our next question. Go right ahead.
Yes, hello there. Good evening, and congratulations on the very strong top line earnings. I have just two questions. I'd like to revisit the production capacity topic, since some headlines mentioned discussions about doubling production capacity — to reach, let's say, 20 to 30 million of production capacity in wearables this year. Should we take that assumption into consideration? Could you give us a bit more color on that? My second question is also about wearables — the Meta Ray-Ban display — the display is a big suc-
It seems Anne-Laure isn't with us on the line anymore. I'll go ahead and take the first question, which is about capacity. I believe this question needs to be viewed from another perspective. The company has ample buildings and plants in place to support the ramp-up in demand as it arrives. Keep in mind that we have a highly modern facility in China, where a completely new building was actually completed over the last 18 months. As you all know, we also have a very large campus that we built in Thailand, where we have what I'd describe as advanced surface that's ready to be equipped. When we need to keep pace with demand, we add a production line — these are now standardized, and we know very well how to equip them — and we're also connected with a Vietnamese partner company that can provide support whenever needed. So we have a capacity setup in place that can track demand, and I think that's the better way to view it, more than anything else.
Our following question is from Hassan Al-Wakeel at Barclays. Kindly proceed.
Good evening, and thanks for taking my questions. I have a couple, please. First, if I could follow up on wearables — your P&L and the business are shifting meaningfully as wearables take a bigger share of your top line. Could you speak to the longer-term benefits from scale and improved unit economics on the EBIT margin, and also gross margin from product bundling? Over the medium term, do you see a wearables margin in line with the group? I ask because your long-term targets broadly imply flat margins. Second, could you please quantify the tariff and Meta dilution headwind in the second half, as you helpfully did in H1, and the work you've been doing to offset tariff? How do you see this in 2026? What was the FX impact at the margin last year? Thank you.
Good evening, Hassan. I'll handle the questions you've raised. To start with AI glasses: the longer-term gain in operating leverage, and what I'd describe as improvement in price mix, is completely captured in the long-term guidance we've just provided. In that guidance, we clearly tie revenue growth to operating profit, and obviously that generates that rate of earnings across the period. Again, I'd say, when you examine price mix, it's obvious. If you look at the collections we're showing today — Ray-Ban Meta, Vanguard, Meta Ray-Ban display — each carries a price point that is higher, significantly higher, than the original product we sold a few years ago, since there's greater technological content and since all those features, which consumers have appreciated extremely, by the way, are clearly producing a positive effect on our products. Keep in mind, when you look at the ecosystem of our wearable AI glasses, that there are always a couple of other add-ons, which obviously support top line, but profitability as well. The first key part is the lenses. 20% of the AI glasses we sell come with prescription lenses, and obviously that's a margin lift that's quite material.
Another key point involves coatings featuring Transitions, which usually reach 40% to 50% penetration in our AI glasses. That clearly provides a benefit. That basically sums up the situation for AI glasses. Once again, you'll observe price mix rising. You'll also have scale on the cost side, which will assist with cost management as well. All of that is essentially already factored into our long-term guidance.
Coming up next, we have a question from Hugo Solvet at BNP Paribas. Go right ahead.
Hey there, hello. Appreciate you fielding my questions, and congrats on the results. I'd like to spare you further talk on smart glasses and instead dig into the base business. Would you be able to walk us through how the sun portfolio excluding smart glasses performed, and are you still observing that halo effect you called out in Q3, and would you anticipate it carrying on?
Returning to the smart glasses topic, I'd like to hear your perspective on how competition might develop, especially with the recent unease ahead of some upcoming rival launches. Thanks.
Hugo, on the eyeglasses sun halo effect — I think we really need to begin viewing glasses, sunglasses or eyeglasses not as a truly separate category, but rather as an expansion of the category for different functionality. We're now starting to consider AI glasses or wearables as genuinely part of our normal portfolio. Then of course, like any big innovation, especially the Ray-Ban display, they'll drive traffic into the store, and honestly, conversion is very high when the product is available, and when it isn't available, we really convert into a different kind of sunglasses or eyeglasses. Of course the halo effect matters quite a bit, but I believe that's really part of the game. We don't view it as something special; it's something that will continue in the future. That's the strategy for how we manage our portfolio. Same for competition: we welcome competition in this new category, because we are 2 years ahead of all others, we have the unique distribution platform, really almost impossible to replicate in a short term — maybe also in the long term, it's not easy. Competition means more investment in the category, and since we lead the category, that means for us we expect an increasing share of the market.
Both of those are positives — a halo effect and competition are genuinely things we’d welcome going forward. Thanks.
Veronika Dubajova from Citi has the next question. Go ahead, please. Oh,
Good evening, and congratulations on a very impressive finish to the year — and frankly, on a very impressive 2025. Thanks for taking my questions. I'll keep it to two. I'm actually going to change it up a little bit and ask about Stellest and your ambitions in the US. Paul, I think based on the disclosure that you've given us, China's about a €300 million or so euro revenue line for Stellest. How long do you think until we get to a similar number in the US? Ultimately, how do you assess the potential in the US market versus China? If you could talk about that, that would be super helpful. Then my second question is going back to wearables. I was hoping maybe you can give us a little bit of a preview around what's in the pipeline for 2026. Obviously noted your comments around it sounds like Nuance Generation 2.0, but to the extent that you can maybe talk upon what's planned on the sort of AI glasses front in terms of iterations in 2026, that would be helpful. Thank you, guys.
Thank you. I believe I have a complete picture, and we're also working to keep our ambitions realistic for what we can accomplish ourselves in the US. Let me share just a few figures: in the US, there are 15 million children aged 5 to 17 whose myopic vision is corrected. In China, that count is, of course, far, far larger. In China, we've observed that myopia solutions have been rolled out progressively to 20% of the children there who receive correction for myopia. If you apply that metric — which, naturally, takes time — we've now had those solutions on the market for 5, 6 years in China. In the US, if you assume it could progressively reach 20% of the children who would take up that technology — though Francesco will remind me that every child ought to be wearing Stellest, and he's correct, since it's genuinely our duty to make it available to any child. That's roughly the order of magnitude we foresee in the US, and most importantly, it's our duty — and the duty of parents and of every stakeholder — to make it available so children in the US can be equipped with this solution, because it's a good solution, it's super efficient.
That's exactly the point. Make sure there's a strong emphasis on that, so this solution can reach millions of children across the US.
There's just one point regarding the Stellest US ambition: we're beginning to grasp that longevity begins when you're young. That's the reason we're driving Stellest so hard. Stellest is able to alter how your myopia progresses, so it will head off the early stage of numerous other ocular pathologies. We think there's also an ethical dimension we need to embrace, since a kid wearing Stellest genuinely has an opportunity for a better life down the road. This is the first time we've had to grapple with that kind of problem. It resembles what happens in the pharma industry, where you must make certain drugs available to everybody, because this will shape the future of your life — not merely correcting something, it's slowing the pathology down. That's genuinely something we're examining, and we're considering how to penetrate the market really well so as to give the information to doctors and to parents. For the wearable pipeline and Nuance, naturally, we believe the portfolio must expand very, very quickly, must reach different segments of our customers, from luxury through to more affordable eyeglasses, and must truly achieve coverage through a much better segmentation approach: female, male, kids, everyone who might have an interest in this new category.
It's not as simple as it is with analog glasses to come out with a new product, but the platform is very solid now. We have more than one platform, each with different capabilities and features, and we're really focused on expanding our portfolio. Same goes for Nuance: we had a wonderful return on the first launch of Nuance. People really have to understand that having Nuance in in-canal traditional hearing aids is a totally different approach. At the first try, you don't see the big benefit that in-canal amplification gives the patient right away, but over the long term, we really had a strong return. People tell us their life changes, and the ability to have clear understanding and conversation in-house with the TV or outside in a noisy place improves a lot. The new lounge that we expect for the second part of the year will really expand the portfolio with something that will see big improvement in amplification and in the power supply, the battery, and many other features, including the capability to take phone calls from our hearing aids out of canal. Thank you.
Our next question is from Thierry Cota at Bank of America. Please go ahead.
Yes, good evening, and thanks so much for taking my questions. First, on the guidance: you mentioned sales and EBIT growing in alignment over the next 5 years. I was wondering whether you expect that alignment to hold more or less in each individual year, or whether we should still see a margin decline at the EBIT level in 2026? Second, regarding Q3, or on Q3, you disclosed how much AI glasses contributed to that quarter's growth on an organic basis. Could you provide us with that same figure, the same number, for Q4, please? Good evening, Thierry. I'll address both of your questions. On the first one, the guidance: we provided and communicated a long-term outlook, and when we do that, we clearly are not giving guidance for any single year. Obviously, some things are already evident for 2026 based on what we see today. We have the annualization of tariffs. As in 2025, we had the tariff impact from the second quarter through the end of '25. That effect will be annualized in 2026. As for FX, unfortunately, it doesn't appear it will be favorable to us in 2026, with the US dollar-euro exchange rate at this level.
Of course, the other point we're aware of is that AI glasses are going to be a significant component of our growth story this year. We're also aware that the newly deployed assets—Paul mentioned the Stellest launch and rollout in the United States as the sole lens solution for managing myopia—will play a role. We know hearing aids are going to keep developing through 2026. We know the AI glasses lineup is going to broaden in 2026. Each of those forms part of this year. Midway through the year we have a checkpoint where we'll assess our trajectory. What I can share with you tonight is that January has already gotten off to a good start. We're posting a double-digit month in January. Clearly, it's the smallest month when it comes to its share of overall revenue. There are 11 months still ahead of us, but it's an encouraging beginning for 2026. Your second question, Thierry, concerned the contribution from AI glasses. I can say that it's fairly clear the AI glasses share of our revenue profile was larger in the second half of the year, especially in the fourth quarter—even more so than in the third quarter.
To repeat, I see this as a logical progression in growing our distribution footprint, which I touched on earlier. On top of that, there may be some seasonality tied to the holidays. Once more, this isn't anything unexpected, given that we continue launching a product that's in strong demand in the market and performs very well across both Direct to Consumer and Professional Solutions.
Our following question is from Richard Felton at Goldman Sachs. Your line is open.
Okay, thank you so much for taking my questions. First, I'd like to follow up on what Veronika asked regarding Stellest in the US. I appreciate the comparison to China, but from what I understand, reimbursement is somewhat better in the US. Could you speak to the current reimbursement coverage for Stellest and what you expect during 2026, and whether it's reasonable that this could potentially drive higher penetration rates than what you mentioned for China? My second question concerns AI glasses. Can you give any color on the acceleration in AI glasses in Q4 by product? Which products within the AI glasses portfolio were driving that acceleration in growth? Thank you.
Reimbursement: you're absolutely right about that. In the US, managed vision care programs are in place, and here's some very encouraging news: Stellest has already been included in what's called the VSP formulary, which means eye care professionals can already see very clearly that it's a product solution that gets reimbursed. That's part of establishing this category, this product, and this solution in the US. You're right that we're examining every angle that will make this — as Francesco and I mentioned — a standard solution for children, for myopic children.
I'll take that second question, Richard. Regarding AI glasses, it's honestly hard for me to single out one particular model for the fourth quarter, since the rollout of the second generation of Ray-Ban Meta went well. There was incredible—truly incredible—curiosity and excitement surrounding the Vanguard launch, and also around the other product we sold toward the end of the third quarter, which is Houston. Meta Ray-Ban display is another item that drew a great deal of curiosity and interest. Essentially all of the appointments at our stores to try on Meta Ray-Ban display were booked through the end of the year. Every one of them has contributed to a successful story in the fourth quarter.
I appreciate everyone joining us again today as well. Your enthusiasm for our company really means a lot, and that was a genuinely interesting question. Hopefully, when we speak next time, we can spend a bit more time on healthcare, predictive medicine, and what we're putting into the eye clinic and the clinical study — that piece is going to matter a great deal for where we're headed, given that eyeglasses are where we are now. Thank you, and talk to you soon.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EssilorLuxottica Société anonyme transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to EssilorLuxottica Société anonyme earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.